Cookie use on MRCVSonline
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive all cookies.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Manuscript calls for collaborative approach to drug development
"We hope our recommendations will reposition comparative oncology canine trials as integral and parallel to human development" - Dr Chand Khanna.
Manuscript will further new initiatives to expand awareness of comparative oncology.

A new WSAVA-supported manuscript has highlighted the value of collaboration between the human and animal pharmaceutical and biotech sectors in drug development.

The manuscript follows a workshop on comparative oncology, hosted by the WSAVA's One Health Committee (WSAVA OHC) at its 2019 World Congress in Toronto. The workshop was led by researchers in human and animal medicine and was attended by academics and industry representatives working in cancer research.

Many cancers that afflict dogs also occur in humans, giving researchers the chance to improve lives by studying cancers and treatments in parallel. Delegates at the workshop included other members of the WSAVA OHC, academics and industry representatives working in cancer research.

In the manuscript, researchers outline new commercial perspectives on the value of closer relationships between the human and animal health pharmaceutical and biotech sectors, to deliver a ‘win/win’ for successful cancer drug development in humans and dogs.

Manuscript author Dr Chand Khanna, from the American College of Veterinary Internal Medicine (Oncology), commented: “We hope our recommendations will reposition comparative oncology canine trials as integral and parallel to human development and that this move will create opportunities for step-wise iteration and the improvements in the human cancer drug development path that are increasingly necessary.”

Dr Michael Lappin, chair of WSAVA One Health Committee, added: “The field of comparative oncology as part of cancer drug development stands out as a successful example of the One Health approach to medicine and this new manuscript presents a nuanced and novel strategy to deliver this translational opportunity.”

The authors and the WSAVA OHC plan to use the manuscript as a springboard for further new initiatives to expand awareness of comparative oncology. They also hope to drive forward its use to create a closer alignment of human and animal health pharma and biotech.

The manuscript, entitled ‘Delivering innovation to oncology drug development through cancer drug DISCO (Development Incentive Strategy using comparative oncology): Perspectives, gaps and solutions’, is published in the journal Annals of Medicine and Clinical Oncology

Become a member or log in to add this story to your CPD history

Tickets on sale for horse welfare conference

News Story 1
 Tickets are now on sale for the 'Welfare and Performance of the Ridden Horse' conference, due to take place at Nottingham University on Saturday, 11 December 2021.

World-renowned researchers, including Prof. Hilary Clayton and Dr Sue Dyson, will deliver the latest research updates. There will also be interactive Q&A sessions throughout the day, interactive polls and a fun evening of entertainment.

Organisers say that in the event of further coronavirus restrictions, day tickets will be transferred to livestream tickets. For more information about the conference and to book your place, click here.  

Click here for more...
News Shorts
More cases of African swine fever confirmed in Germany

More cases of African swine fever (ASF) have been confirmed in wild boar in Germany.

According to Pig World, 20 outbreaks have been identified in two districts - Brandenburg, where the original case confirmed on September 10 was found, and near the town of Neuzelle, some 7.5 km away.

The finding represents a further seven cases confirmed by Germany's Friedrich-Loeffler Institute. A Central Crisis Team has been established to coordinate the response to the outbreak.